Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell ...

Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA ...

Vertex Pharmaceuticals (VRTX) is facing technical challenges, with its stock forming a Death Cross and down 15% in 6 months.

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle ...

Vertex aims to further bolster its gene-editing therapy pipeline by using Orna's lipid nanoparticle delivery technologies during the three-year collaboration.

Wake up with Breakfast news in your inbox every market day. Sign Up For Free » Since November 2023, CRISPR Therapeutics has ...

Read about how Crispr's robust pipeline for cardiovascular diseases holds blockbuster potential, with top-line results ...

Investors looking for stocks that can make dramatic gains can find some in the biopharmaceutical industry. Right now, there ...

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock. This data can help you ...

This year saw several advancements across medicine, space technology, and AI that extend our knowledge in consequential ways.

Due to manufacturing complexities, insurance delays, and the extensive preparation involved for patients, few individuals in the US have been dosed with Casgevy since it became commercially available.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trials in people with ...